Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 12, 2017. The document serves as a transaction notification reporting insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. The filing does not contain operational updates, earnings results, or strategic business commentary.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £15.96 per share.
- Transaction Volume: 16 shares per individual (comprising 8 partnership shares and 8 matching shares).
- Transaction Date: January 11, 2017.
- Exchange: London Stock Exchange (XLON).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses routine acquisitions of shares under the Company's ShareReward Plan by senior executives.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a compliance disclosure regarding executive compensation and share ownership.
Important Facts for Investors to Verify
- Executive Participation: Verify the participation of key executives in the ShareReward Plan, including CEO Sir Andrew Witty, CEO Designate Ms. E. Walmsley, CFO Mr. S. Dingemans, and other senior leaders.
- Transaction Consistency: Note that all reported transactions occurred on the same date (January 11, 2017) at the same price (£15.96) with identical volume structures (16 shares total per person).
- Plan Mechanics: Confirm the structure of the ShareReward Plan, specifically the 1:1 matching ratio between partnership shares and matching shares.
- Regulatory Compliance: Acknowledge that this filing satisfies Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 regarding foreign issuer reporting.